Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schmidinger

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Current Opinion in Urology|October 19, 2017
Clinical decision-making for immunotherapy in metastatic renal cell carcinomaManuela Schmidinger
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapyManuela Schmidinger
The Oncologist|November 18, 2017
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell CarcinomaManuela Schmidinger, Romano Danesi
Current Opinion in Urology|July 7, 2015
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCESManuela Schmidinger, Janet Wittes
Cancer Treatment Reviews|February 19, 2010
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinomaManuela Schmidinger, Joaquim Bellmunt
Cancer Treatment Reviews|February 24, 2009
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapyManuela Schmidinger, Christoph C Zielinski
International Journal of Urology : Official Journal of the Japanese Urological Association|May 16, 2012
Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaManuela Schmidinger, Jutta Bergler-Klein
Journal of Cancer Research and Clinical Oncology|May 11, 2010
Defining risk status in the first-line treatment of metastatic renal cell carcinomaManuela Schmidinger, Christoph C Zielinski
Current Opinion in Urology|October 22, 2024
Guiding treatment decisions in renal cell carcinoma: the role of biomarkers and clinical factorsIrene Huebner-Resch, Manuela Schmidinger
Therapeutic Advances in Urology|October 2, 2012
Experience with sunitinib in the treatment of metastatic renal cell carcinomaManuela Schmidinger, James Larkin, Alain Ravaud
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Current Opinion in Urology|October 19, 2017
Clinical decision-making for immunotherapy in metastatic renal cell carcinomaManuela Schmidinger
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapyManuela Schmidinger
The Oncologist|November 18, 2017
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell CarcinomaManuela Schmidinger, Romano Danesi
Current Opinion in Urology|July 7, 2015
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCESManuela Schmidinger, Janet Wittes
Cancer Treatment Reviews|February 19, 2010
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinomaManuela Schmidinger, Joaquim Bellmunt
Cancer Treatment Reviews|February 24, 2009
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapyManuela Schmidinger, Christoph C Zielinski
International Journal of Urology : Official Journal of the Japanese Urological Association|May 16, 2012
Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaManuela Schmidinger, Jutta Bergler-Klein
Journal of Cancer Research and Clinical Oncology|May 11, 2010
Defining risk status in the first-line treatment of metastatic renal cell carcinomaManuela Schmidinger, Christoph C Zielinski
Current Opinion in Urology|October 22, 2024
Guiding treatment decisions in renal cell carcinoma: the role of biomarkers and clinical factorsIrene Huebner-Resch, Manuela Schmidinger
Therapeutic Advances in Urology|October 2, 2012
Experience with sunitinib in the treatment of metastatic renal cell carcinomaManuela Schmidinger, James Larkin, Alain Ravaud
Pageof 12